Lonza Group (FRA:LO3) Long-Term Debt: €4,154 Mil (As of Dec. 2025)


FRA:LO3 Lonza Group Ltd FRA:LO3
83 GF Score
Price €638.00
GF Value €647.98
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lonza Group Long-Term Debt?

Lonza Group FRA:LO3 +2.24% 83 Long-Term Debt is €4,154 Mil as of Dec. 2025. GuruFocus rates FRA:LO3 with a GF Score™ of 83/100 and a GF Value™ of €647.98 (Fairly Valued). The stock has 4 warning signs investors should review.

Lonza Group's Long-Term Debt for the quarter that ended in Dec. 2025 was €4,154 Mil.

Lonza Group's quarterly Long-Term Debt declined from Dec. 2024 (€4,544 Mil) to Jun. 2025 (€4,477 Mil) and declined from Jun. 2025 (€4,477 Mil) to Dec. 2025 (€4,154 Mil).

Lonza Group's annual Long-Term Debt increased from Dec. 2023 (€2,768 Mil) to Dec. 2024 (€4,544 Mil) but then declined from Dec. 2024 (€4,544 Mil) to Dec. 2025 (€4,154 Mil).

Lonza Group  (FRA:LO3) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Lonza Group Long-Term Debt Related Terms

Lonza Group Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Lonza Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lonza Group Long-Term Debt Chart

Lonza Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,146.68 1,574.68 2,767.54 4,543.64 4,153.73

Lonza Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,767.54 3,783.35 4,543.64 4,476.80 4,153.73
FRA:LO3
83GF Score
Lonza Group Ltd FRA:LO3
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €4,154 Mil mean?
Lonza Group (FRA:LO3) has a Long-Term Debt of €4,154 Mil as of Dec. 2025.
Is Lonza Group's Long-Term Debt too high?
Lonza Group's current Long-Term Debt is €4,154 Mil. Overall, Lonza Group has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Long-Term Debt compare to TMO and DHR?
Lonza Group's Long-Term Debt of €4,154 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Lonza Group's current Long-Term Debt is €4,154 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (FRA:LO3) is currently considered Fairly Valued. The stock's GF Value™ is €647.98, compared to a current price of €638.00 — trading 1.5% below its estimated fair value. The current Long-Term Debt is €4,154 Mil. Lonza Group's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Lonza Group (FRA:LO3), the current Long-Term Debt is €4,154 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lonza Group (FRA:LO3) Overvalued in 2026?

Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued. The current stock price of €638.00 is trading 1.5% below its estimated GF Value™ of €647.98. GuruFocus considers Lonza Group to be Fairly Valued.

Key valuation signals for FRA:LO3:

  • Long-Term Debt: €4,154 Mil
  • GF Value™: €647.98 vs. price of €638.00 (1.5% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the FRA:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lonza Group Business Description

Address Muenchensteinerstrasse 38, Basel, CHE, 4002
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
83GF Score

Get the complete analysis for FRA:LO3

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€638.00
Price
€647.98
GF Value